Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alisertib + erlotinib
- Development stage
- Unknown
- Lead developer
- Puma Biotechnology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of alisertib (MLN-8237), an oral selective Aurora kinase A inhibitor, and erlotinib, an oral reversible tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR). This combination has shown synergistic antitumor activity in preclinical studies and has been evaluated in clinical trials for patients with recurrent or metastatic EGFR wild-type non-small cell lung cancer (NSCLC). Recent research also suggests potential efficacy in KRAS-mutated NSCLC.
02
Targets
EGFR (Epidermal growth factor receptor)AURKA (Aurora kinase A)
Beyond the preview
Go deeper on alisertib + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alisertib + erlotinib.